Fig. 1.

In vivo efficacy of CT-P59 against Gamma variant in mice. Vehicle and 5, 20, 40 and 80 mg/kg of CT-P59 were administered intraperitoneally 8 h after virus inoculation. Body weights and survival rates were monitored daily (A, B). The weight per mouse on day 0 was used as a baseline, and weight change was determined relative to baseline. 30% or higher of weight loss was considered to be dead. Four animals each were euthanized for virus titration at 3 dpi and 6 dpi, respectively. The virus titers from lung tissue was measured (C, D) using plaque assay. Alphabets and asterisks indicates statistical significance between the virus only and each treatment group as determined by one-way ANOVA followed by a Dunnett's post-hoc test. a denotes p < 0.0001 between control and CT-P59 treatment groups (pooled). b denotes p < 0.01 to p < 0.05 between control and CT-P59 treatment group at 80 mg/kg c denotes p < 0.0001 to p < 0.01 between control and CT-P59 treatment groups at 5, 20, 40 and 80 mg/kg d denotes p < 0.0001 to p < 0.001 between control and CT-P59 treatment groups at 5, 20, 40 and 80 mg/kg ∗ indicates P < 0.05, and ∗∗∗∗ indicates P < 0.0001.